MediWound Ltd Cash Flow Conversion Efficiency
MediWound Ltd cash flow conversion efficiency. Based on the latest financial reports, MediWound Ltd (M8W) has a cash flow conversion efficiency ratio of -0.069x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.02 Million ≈ $-3.53 Million USD) by net assets (€43.63 Million ≈ $51.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MediWound Ltd (2016–2025)
Cash flow conversion efficiency of MediWound Ltd from 2016 to 2025. This chart illustrates how MediWound Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for MediWound Ltd for real-time trading data and today's change.
MediWound Ltd Cash Flow Conversion Ratio Explained
MediWound Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MediWound Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MediWound Ltd ranked by their cash flow conversion efficiency. Also see MediWound Ltd (M8W) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AGILYX ASA NK -02
F:5NQ
|
N/A |
|
Indian Hume Pipe Company Limited
NSE:INDIANHUME
|
-0.005x |
|
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
|
-0.363x |
|
AYM Syntex Limited
NSE:AYMSYNTEX
|
0.065x |
|
AMA Group Limited
F:KC7
|
0.047x |
|
Bygg Partner i Dalarna Holding AB
ST:BYGGP
|
0.129x |
|
ARKO Petroleum Corp.
NASDAQ:APC
|
0.040x |
|
Latécoère S.A.
PA:LAT
|
0.109x |
Annual Cash Flow Conversion Efficiency for MediWound Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of MediWound Ltd from 2016 to 2025. Review how much free cash does MediWound Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €43.63 Million ≈ $51.01 Million |
€-16.12 Million ≈ $-18.85 Million |
-0.369x | +15.51% |
| 2024-12-31 | €31.15 Million ≈ $36.42 Million |
€-13.62 Million ≈ $-15.93 Million |
-0.437x | -32.03% |
| 2023-12-31 | €31.59 Million ≈ $36.94 Million |
€-10.46 Million ≈ $-12.23 Million |
-0.331x | +69.58% |
| 2022-12-31 | €10.91 Million ≈ $12.76 Million |
€-11.88 Million ≈ $-13.89 Million |
-1.089x | -155.96% |
| 2021-12-31 | €-4.58 Million ≈ $-5.36 Million |
€-8.92 Million ≈ $-10.42 Million |
1.946x | +305.23% |
| 2020-12-31 | €7.27 Million ≈ $8.50 Million |
€-6.89 Million ≈ $-8.06 Million |
-0.948x | -273.51% |
| 2019-12-31 | €15.17 Million ≈ $17.73 Million |
€8.29 Million ≈ $9.69 Million |
0.546x | +140.34% |
| 2018-12-31 | €8.97 Million ≈ $10.49 Million |
€-12.15 Million ≈ $-14.21 Million |
-1.355x | +20.80% |
| 2017-12-31 | €9.62 Million ≈ $11.25 Million |
€-16.45 Million ≈ $-19.24 Million |
-1.710x | +19.18% |
| 2016-12-31 | €7.77 Million ≈ $9.08 Million |
€-16.45 Million ≈ $-19.23 Million |
-2.116x | -- |
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn cen… Read more